Vaccination of cancer patients with tumor-specific antigens, and biology of cytokines

Projektinformationen

TUMOR VACCINES, CYTO

ID Finanzhilfevereinbarung: QLG1-CT-2000-60013

Projekt abgeschlossen

Startdatum 21 Januar 2002

Enddatum 20 Januar 2006

Finanziert unter

• Specific Programme for research, technological development and demonstration on "Quality of life and management of living resources", 1998-2002

Gesamtkosten € 480 000,00

EU-Beitrag € 480 000,00

Koordiniert durch

CHRISTIAN DE DUVE INSTITUTE OF CELLULAR PATHOLOGY
Belgium

Ziel

Our groups work on the characterization of human tumour-specific antigens recognized by T lymphocytes, the use of these antigens for therapeutic vaccination of cancer patients, and the biology of new cytokines.

Wissenschaftliches Gebiet

• medical and health sciences › clinical medicine › oncology

Programm/Programme

• FP5-LIFE QUALITY - Specific Programme for research, technological development and demonstration on "Quality of life and management of living resources", 1998-2002

Thema/Themen

• 1.1.1.-7. - Chronic and degenerative diseases, cancer, diabetes, cardivascular diseases and rare diseases

Aufforderung zur Vorschlagseinreichung

Data not available

Finanzierungsplan

BUR - Bursaries, grants, fellowships

Koordinator

CHRISTIAN DE DUVE INSTITUTE OF CELLULAR PATHOLOGY

• EU-Beitrag: Keine Daten
• Adresse: Avenue Hippocrate 74 ; 1200 BRUXELLES ; Belgien
• Gesamtkosten: Keine Daten